Grundläggande statistik
| CIK | 1386858 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Hyperion Therapeutics Inc
SEC Filings (Chronological Order)
Denna sida innehåller en komplett, kronologisk lista över SEC-arkiveringar, exklusive ägande-arkiveringar som vi tillhandahåller på andra ställen.
| February 11, 2016 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Hyperion Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 44915N101 (CUSIP Number) December 31, 2015 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designat |
|
| May 18, 2015 |
15-12B UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 15 CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. Commission File Number 001-35614 HYPERION THERAPEUTICS, INC. (Exact name of registrant as sp |
|
| May 15, 2015 |
SC 13D/A 1 v410450sc13da.htm FORM SC 13D/A CUSIP NO. 44915N101 13D Page 1 of 8 SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13D (RULE 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(a) (Amendment No. 6)* Hyperion Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share ( |
|
| May 11, 2015 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 2)* Hyperion Therapeutics, Inc. (Name of Issuer) Common Stock, $.0001 par value (Title of Class of Securities) 44915N101 (CUSIP Number) Louis S. Citron, Esq. New Enterprise Associates 1954 Greenspring Drive, Suite 600 Timonium, MD 21093 (410) 842-4000 (Name, |
|
| May 7, 2015 |
S-8 POS As filed with the Securities and Exchange Commission on May 7, 2015 Registration No. |
|
| May 7, 2015 |
RW Hyperion Therapeutics, Inc. 2000 Sierra Point Parkway, Suite 400 Brisbane, CA 94005 May 7, 2015 VIA EDGAR Daniel F. Duchovny Securities and Exchange Commission Division of Corporation Finance 100 F Street N.E. Washington, D.C. 20549 RE: Hyperion Therapeutics, Inc. Registration Statement on Form S-3 (File No. 333-190624) Filed August 14, 2013 Application for Withdrawal Dear Mr. Duchovny: Pursuan |
|
| May 7, 2015 |
S-8 POS As filed with the Securities and Exchange Commission on May 7, 2015 Registration No. |
|
| May 7, 2015 |
Horizon Pharma plc Announces Results of Tender Offer EX-99.A5.IV Exhibit (a)(5)(iv) Horizon Pharma plc Announces Results of Tender Offer DUBLIN, Ireland May 7, 2015 Horizon Pharma plc (Horizon) (NASDAQ: HZNP) today announced the results of its tender offer to purchase all of the outstanding shares of common stock of Hyperion Therapeutics, Inc. (Hyperion) (NASDAQ: HPTX) for $46.00 per share in cash, net to the seller in cash, without interest |
|
| May 7, 2015 |
AMENDED AND RESTATED CERTIFICATE OF INCORPORATION HORIZON THERAPEUTICS, INC. EX-3.1 2 d921752dex31.htm EX-3.1 Exhibit 3.1 AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF HORIZON THERAPEUTICS, INC. I. The name of this corporation is Horizon Therapeutics, Inc. II. The registered office of the corporation in the State of Delaware shall be 3411 Silverside Road, Rodney Bldg, Suite 104, City of Wilmington, County of New Castle County, 19810 and the name of the registered ag |
|
| May 7, 2015 |
SC 14D9/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (Amendment No. 3) Solicitation/Recommendation Statement Under Section 14(d)(4) of the Securities Exchange Act of 1934 HYPERION THERAPEUTICS, INC. (Name of Subject Company) HYPERION THERAPEUTICS, INC. (Name of Person Filing Statement) Common Stock, par value $0.0001 per share (Title of Class of Securiti |
|
| May 7, 2015 |
EX-3.2 3 d921752dex32.htm EX-3.2 Exhibit 3.2 AMENDED AND RESTATED BYLAWS OF HORIZON THERAPEUTICS, INC. (A DELAWARE CORPORATION) AMENDED AND RESTATED BYLAWS OF HORIZON THERAPEUTICS, INC. (A DELAWARE CORPORATION) ARTICLE I OFFICES Section 1. Registered Office. The registered office of the corporation in the State of Delaware shall be in the City of Wilmington, County of New Castle. Section 2. Other |
|
| May 7, 2015 |
8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 7, 2015 HYPERION THERAPEUTICS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-35614 61-1512713 (State or Other Jurisdiction of Incorporation) (Commis |
|
| May 7, 2015 |
S-8 POS As filed with the Securities and Exchange Commission on May 7, 2015 Registration No. |
|
| May 7, 2015 |
SC TO-T/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO Tender Offer Statement Under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 (Amendment No. 5) Hyperion Therapeutics, Inc. (Name of Subject Company) Ghrian Acquisition Inc. (Name of Offeror) A Wholly Owned Subsidiary of Horizon Pharma, Inc. (Parent of Offeror) An Indirect Wholly-Owned |
|
| May 7, 2015 |
S-8 POS As filed with the Securities and Exchange Commission on May 7, 2015 Registration No. |
|
| May 6, 2015 |
COMPLETION OF PHASE III CLINICAL TRIAL, OPTION AND MUTUAL RELEASE AGREEMENT Exhibit 10.1 *** INDICATES MATERIAL THAT WAS OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT WAS REQUESTED. ALL SUCH OMITTED MATERIAL WAS FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 PROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. Execution COMPLETION OF PHASE III CLINICAL TRIAL, OPTION AND MUTUAL RELEASE AGREEMENT This COMPLETION OF PHASE III |
|
| May 6, 2015 |
HPTX FORM 10-Q (Quarterly Report) Form 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. |
|
| April 30, 2015 |
Horizon Pharma plc Announces Waiver of Financing Proceeds Condition EX-99.A5.III Exhibit (a)(5)(iii) Horizon Pharma plc Announces Waiver of Financing Proceeds Condition (DUBLIN, Ireland and BRISBANE, Calif. ? April 30, 2015) ? Horizon Pharma plc (NASDAQ: HZNP) a specialty biopharmaceutical company focused on improving patients? lives by identifying, developing, acquiring and commercializing differentiated products that address unmet medical needs, today announced |
|
| April 30, 2015 |
EX-99.(A)(11) 2 d919212dex99a11.htm EX-99.(A)(11) Exhibit (a)(11) Horizon Pharma plc Announces Expiration of HSR Waiting Period for Proposed Hyperion Therapeutics, Inc. Acquisition (DUBLIN, Ireland and BRISBANE, Calif. – April 29, 2015) – Horizon Pharma plc (NASDAQ: HZNP) today announced the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended (“HSR”) expired e |
|
| April 30, 2015 |
SC TO-T/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO Tender Offer Statement Under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 (Amendment No. 4) Hyperion Therapeutics, Inc. (Name of Subject Company) Ghrian Acquisition Inc. (Name of Offeror) A Wholly Owned Subsidiary of Horizon Pharma, Inc. (Parent of Offeror) An Indirect Wholly-Owned |
|
| April 30, 2015 |
Exhibit (a)(5)(ii) Horizon Pharma plc Announces Expiration of HSR Waiting Period for Proposed Hyperion Therapeutics, Inc. |
|
| April 30, 2015 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (Amendment No. 2) Solicitation/Recommendation Statement Under Section 14(d)(4) of the Securities Exchange Act of 1934 HYPERION THERAPEUTICS, INC. (Name of Subject Company) HYPERION THERAPEUTICS, INC. (Name of Person Filing Statement) Common Stock, par value $0.0001 per share (Title of Class of Securities) 44915N |
|
| April 29, 2015 |
10-K/A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| April 27, 2015 |
SC TO-T/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO Tender Offer Statement Under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 (Amendment No. 3) Hyperion Therapeutics, Inc. (Name of Subject Company) Ghrian Acquisition Inc. (Name of Offeror) A Wholly Owned Subsidiary of Horizon Pharma, Inc. (Parent of Offeror) An Indirect Wholly-Owned |
|
| April 23, 2015 |
HPTX / Hyperion Therapeutics Inc / GAMCO INVESTORS, INC. ET AL Activist Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 Hyperion Therapeutics, Inc. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 44915N101 (CUSIP Number) David Goldman GAMCO Investors, Inc. One Corporate Center Rye, New York 10580-1435 (914) 921-5000 (Name, Address and Telephone Number of Person A |
|
| April 22, 2015 |
SC 14D9/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (Amendment No. 1) Solicitation/Recommendation Statement Under Section 14(d)(4) of the Securities Exchange Act of 1934 HYPERION THERAPEUTICS, INC. (Name of Subject Company) HYPERION THERAPEUTICS, INC. (Name of Person Filing Statement) Common Stock, par value $0.0001 per share (Title of Class of Securiti |
|
| April 22, 2015 |
CORRESP April 21, 2015 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549-3628 Attn: Daniel F. Duchovny, Special Counsel Re: Hyperion Therapeutics, Inc. Schedule 14D-9 filed April 9, 2015 SEC File No. 005-86934 Dear Mr. Duchovny: This letter responds to the letter, dated April 20, 2015 from the staff (the ?Staff?) of the Secu |
|
| April 22, 2015 |
SC TO-T/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO Tender Offer Statement Under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 (Amendment No. 2) Hyperion Therapeutics, Inc. (Name of Subject Company) Ghrian Acquisition Inc. (Name of Offeror) A Wholly Owned Subsidiary of Horizon Pharma, Inc. (Parent of Offeror) An Indirect Wholly-Owned |
|
| April 14, 2015 |
SC TO-T/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO Tender Offer Statement Under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 (Amendment No. 1) Hyperion Therapeutics, Inc. (Name of Subject Company) Ghrian Acquisition Inc. (Name of Offeror) A Wholly Owned Subsidiary of Horizon Pharma, Inc. (Parent of Offeror) An Indirect Wholly-Owned |
|
| April 9, 2015 |
EX-(a)(1)(vi) Exhibit (a)(1)(vi) This announcement is neither an offer to purchase nor a solicitation of an offer to sell Shares (as defined below). |
|
| April 9, 2015 |
Hyperion Therapeutics, Inc. 2000 Sierra Point Parkway, Suite 400 Brisbane, CA 94005 EX-(d)(3) Exhibit (d)(3) Execution Copy Hyperion Therapeutics, Inc. 2000 Sierra Point Parkway, Suite 400 Brisbane, CA 94005 March 8, 2015 Horizon Pharma plc Connaught House, 1st Floor Dublin 4, Ireland Attention: Timothy Walbert Confidentiality Agreement Ladies and Gentlemen: We are in receipt of the letter from Timothy P. Walbert, Chairman, President and Chief Executive Officer of Horizon Pharma |
|
| April 9, 2015 |
Results of Operations and Financial Condition Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 9, 2015 HYPERION THERAPEUTICS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-35614 61-1512713 (State or Other Jurisdiction of Incorporation) |
|
| April 9, 2015 |
SC TO-T UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO Tender Offer Statement Under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 Hyperion Therapeutics, Inc. (Name of Subject Company) Ghrian Acquisition Inc. (Name of Offeror) A Wholly Owned Subsidiary of Horizon Pharma, Inc. (Parent of Offeror) An Indirect Wholly-Owned Subsidiary of Horizo |
|
| April 9, 2015 |
EX-99.A.1.II 3 d903951dex99a1ii.htm EX-(A)(1)(II) Exhibit (a)(1)(ii) LETTER OF TRANSMITTAL To Tender Shares of Common Stock and the Associated Rights to Purchase Capital Stock of HYPERION THERAPEUTICS, INC. at $46.00 Net per Share Pursuant to the Offer to Purchase dated April 9, 2015 by GHRIAN ACQUISITION INC., a wholly owned subsidiary of HORIZON PHARMA, INC., a wholly owned subsidiary of HORIZON |
|
| April 9, 2015 |
Form 8-K/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K/A Amendment No. 1 CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 29, 2015 Horizon Pharma Public Limited Company (Exact name of registrant as specified in its charter) Ireland 001-35238 Not Applicable (State or oth |
|
| April 9, 2015 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits 8-K/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K/A (Amendment No. 1) CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 9, 2015 (March 29, 2015) HYPERION THERAPEUTICS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-35614 61-1512713 (State or Oth |
|
| April 9, 2015 |
EX-99.A.1.I 2 d903951dex99a1i.htm EX-(A)(1)(I) Table of Contents Exhibit (a)(1)(i) Offer to Purchase for Cash All Outstanding Shares of Common Stock of Hyperion Therapeutics, Inc., at $46.00 NET PER SHARE by Ghrian Acquisition Inc. a wholly owned subsidiary of Horizon Pharma, Inc. THE OFFER AND WITHDRAWAL RIGHTS EXPIRE AT 12.01 AM (NEW YORK CITY TIME) ON MAY 7, 2015, UNLESS THE OFFER IS EXTENDED. |
|
| April 9, 2015 |
EX-2.1 2 d907599dex21.htm EX-2.1 Exhibit 2.1 EXECUTION AGREEMENT AND PLAN OF MERGER among: HORIZON PHARMA, INC. a Delaware corporation, GHRIAN ACQUISITION INC., a Delaware corporation, and HYPERION THERAPEUTICS, INC., a Delaware corporation Dated as of March 29, 2015 TABLE OF CONTENTS Page ARTICLE I. THE OFFER 1.1 The Offer 6 1.2 Company Actions 9 ARTICLE II. THE MERGER 2.1 Merger of Purchaser int |
|
| April 9, 2015 |
EX-(a)(1)(iii) Exhibit (a)(1)(iii) NOTICE OF GUARANTEED DELIVERY For Tender of All Outstanding Shares of Common Stock and the Associated Rights to Purchase Capital Stock of HYPERION THERAPEUTICS, INC. |
|
| April 9, 2015 |
EX-2.1 Exhibit 2.1 EXECUTION AGREEMENT AND PLAN OF MERGER among: HORIZON PHARMA, INC. a Delaware corporation, GHRIAN ACQUISITION INC., a Delaware corporation, and HYPERION THERAPEUTICS, INC., a Delaware corporation Dated as of March 29, 2015 TABLE OF CONTENTS Page ARTICLE I. THE OFFER 1.1 The Offer 6 1.2 Company Actions 9 ARTICLE II. THE MERGER 2.1 Merger of Purchaser into the Company 10 2.2 Effec |
|
| April 9, 2015 |
8-K/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K/A (Amendment No. 1) CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 9, 2015 (March 29, 2015) HYPERION THERAPEUTICS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-35614 61-1512713 (State or Oth |
|
| April 9, 2015 |
EX-(a)(1)(v) Exhibit (a)(1)(v) Offer To Purchase For Cash All Outstanding Shares of Common Stock and the Associated Rights to Purchase Capital Stock of HYPERION THERAPEUTICS, INC. |
|
| April 9, 2015 |
EX-2.1 Exhibit 2.1 EXECUTION AGREEMENT AND PLAN OF MERGER among: HORIZON PHARMA, INC. a Delaware corporation, GHRIAN ACQUISITION INC., a Delaware corporation, and HYPERION THERAPEUTICS, INC., a Delaware corporation Dated as of March 29, 2015 TABLE OF CONTENTS Page ARTICLE I. THE OFFER 1.1 The Offer 6 1.2 Company Actions 9 ARTICLE II. THE MERGER 2.1 Merger of Purchaser into the Company 10 2.2 Effec |
|
| April 9, 2015 |
EX-(a)(1)(iv) Exhibit (a)(1)(iv) Offer To Purchase For Cash All Outstanding Shares of Common Stock and the Associated Rights to Purchase Capital Stock of HYPERION THERAPEUTICS, INC. |
|
| April 9, 2015 |
SC 14D9 Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| April 7, 2015 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 1)* Hyperion Therapeutics, Inc. (Name of Issuer) Common Stock, $.0001 par value (Title of Class of Securities) 44915N101 (CUSIP Number) Louis S. Citron, Esq. New Enterprise Associates 1954 Greenspring Drive, Suite 600 Timonium, MD 21093 (410) 842-4000 (Name, |
|
| April 3, 2015 |
HPTX / Hyperion Therapeutics Inc / SOFINNOVA VENTURE PARTNERS VII L P - SC 13D/A Activist Investment CUSIP NO. 44915N101 13D Page 1 of 10 SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13D (RULE 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(a) (Amendment No. 5)* Hyperion Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 44915N101 (C |
|
| March 31, 2015 |
Exhibit 2.2 TENDER AND SUPPORT AGREEMENT THIS TENDER AND SUPPORT AGREEMENT (this Agreement) is entered into as of March 29, 2015, by and among Horizon Pharma, Inc., a Delaware corporation (Parent), Ghrian Acquisition Inc., a Delaware corporation and wholly owned subsidiary of Parent (Purchaser), and (Stockholder). RECITALS A. Stockholder is a holder of record and the beneficial owner (wi |
|
| March 31, 2015 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 29, 2015 Horizon Pharma Public Limited Company (Exact name of registrant as specified in its charter) Ireland 001-35238 Not Applicable (State or other jurisdiction of incorporat |
|
| March 31, 2015 |
CITIGROUP GLOBAL MARKETS INC. 390 Greenwich Street New York, New York 10013 EX-99.1 Exhibit 99.1 Execution Version CITIGROUP GLOBAL MARKETS INC. 390 Greenwich Street New York, New York 10013 JEFFERIES FINANCE LLC 520 Madison Avenue New York, New York 10022 March 29, 2015 Horizon Pharma, Inc. c/o Horizon Pharma Public Limited Company Connaught House, 1 Floor 1 Burlington Road, Dublin 4, Ireland Attention: Paul W. Hoelscher, Executive Vice President and Chief Financial Offi |
|
| March 31, 2015 |
EX-2.1 2 d899083dex21.htm EX-2.1 Exhibit 2.1 EXECUTION AGREEMENT AND PLAN OF MERGER among: HORIZON PHARMA, INC. a Delaware corporation, GHRIAN ACQUISITION INC., a Delaware corporation, and HYPERION THERAPEUTICS, INC., a Delaware corporation Dated as of March 29, 2015 TABLE OF CONTENTS Page ARTICLE I. THE OFFER 1.1 The Offer 6 1.2 Company Actions 9 ARTICLE II. THE MERGER 2.1 Merger of Purchaser int |
|
| March 30, 2015 |
EX-99.2 Exhibit 99.2 Horizon Pharma plc Acquisition of Hyperion Therapeutics March 30, 2015 Non-Confidential Information ? Horizon Pharma plc Forward-Looking Statements This presentation contains forward-looking statements, including, but not limited to, statements related to Horizon?s anticipated acquisition of Hyperion Therapeutics, Inc. and the timing and benefits thereof, estimated future fina |
|
| March 30, 2015 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Other Events Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 30, 2015 HYPERION THERAPEUTICS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-35614 61-1512713 (State or Other Jurisdiction of Incorporation) |
|
| March 30, 2015 |
SC 14D9 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (Rule 14d-101) Solicitation/Recommendation Statement Under Section 14(d)(4) of the Securities Exchange Act of 1934 HYPERION THERAPEUTICS, INC. (Name of Subject Company) HYPERION THERAPEUTICS, INC. (Name of Person Filing Statement) Common Stock, par value $0.0001 per share (Title of Class of Securities) 4 |
|
| March 30, 2015 |
EX-99.1 4 d899299dex991.htm EX-99.1 Exhibit 99.1 Horizon Pharma plc to Acquire Hyperion Therapeutics, Inc. for $46.00 per share or $1.1 Billion in Cash — Addition of RAVICTI® (glycerol phenylbutyrate) Oral Liquid and BUPHENYL® (sodium phenylbutyrate) Tablets and Powder Significantly Expands Horizon’s Orphan Business – — Transaction is Expected to be Immediately Accretive to Adjusted Earnings Per S |
|
| March 30, 2015 |
EX-99.1 Exhibit 99.1 Horizon Pharma plc to Acquire Hyperion Therapeutics, Inc. for $46.00 per share or $1.1 Billion in Cash ? Addition of RAVICTI? (glycerol phenylbutyrate) Oral Liquid and BUPHENYL? (sodium phenylbutyrate) Tablets and Powder Significantly Expands Horizon?s Orphan Business ? ? Transaction is Expected to be Immediately Accretive to Adjusted Earnings Per Share and Contribute Approxim |
|
| March 30, 2015 |
EX-2.1 Exhibit 2.1 EXECUTION AGREEMENT AND PLAN OF MERGER among: HORIZON PHARMA, INC. a Delaware corporation, GHRIAN ACQUISITION INC., a Delaware corporation, and HYPERION THERAPEUTICS, INC., a Delaware corporation Dated as of March 29, 2015 TABLE OF CONTENTS Page ARTICLE I. THE OFFER 1.1 The Offer 6 1.2 Company Actions 9 ARTICLE II. THE MERGER 2.1 Merger of Purchaser into the Company 10 2.2 Effec |
|
| March 30, 2015 |
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 29, 2015 Horizon Pharma Public Limited Company (Exact name of registrant as specified in its charter) Ireland 001-35238 Not Applicable (State or other jurisdiction of i |
|
| March 30, 2015 |
EX-2.2 Exhibit 2.2 TENDER AND SUPPORT AGREEMENT THIS TENDER AND SUPPORT AGREEMENT (this ?Agreement?) is entered into as of March 29, 2015, by and among Horizon Pharma, Inc., a Delaware corporation (?Parent?), Ghrian Acquisition Inc., a Delaware corporation and wholly owned subsidiary of Parent (?Purchaser?), and (?Stockholder?). RECITALS A. Stockholder is a holder of record and the ?beneficial own |
|
| March 12, 2015 |
Amendment no. 2 to Schedule 13D UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 2)* Hyperion Therapeutics, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 44915N 101 (CUSIP Number) Judy Koh Chief Financial Officer Bay City Capital LLC 750 Battery Street, Suite 400 San Francisco, CA 94111 |
|
| February 26, 2015 |
Hyperion Therapeutics Announces Fourth Quarter and Full Year 2014 Financial Results EXHIBIT 99.1 Hyperion Therapeutics Announces Fourth Quarter and Full Year 2014 Financial Results UCD Product Portfolio Generates $113.6 Million for Fiscal Year 2014 and $30.8 Million in Net Sales During the Fourth Quarter of 2014 - Company Generates $31 Million in Operating Cash Flows in 2014 - Company to Host Conference Call Today at 4:30 p.m. ET (1:30 p.m. PT) BRISBANE, Calif., Feb. 26, 2015 (GL |
|
| February 26, 2015 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event Reported): February 26, 2015 HYPERION THERAPEUTICS, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-35614 61-1512713 (State or Other Jurisdiction of Incorporation) (Commissi |
|
| February 17, 2015 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 16, 2015 HYPERION THERAPEUTICS, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-35614 61-1512713 (State or Other Jurisdiction of Incorporation) |
|
| February 17, 2015 |
SC 13G 1 hptx21315.htm CONSONANCE CAPITAL MANAGEMENT LP UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Hyperion Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 44915N101 (CUSIP Number) December 31, 2014 (Date of Event which Requires Filing o |
|
| February 17, 2015 |
EX-99.1 Exhibit 99.1 Hyperion Therapeutics Enters Into Completion of Phase III Clinical Trial, Option and Mutual Release Agreement with Clal Biotechnology Industries and Yeda Research and Development Company BRISBANE, Calif, Feb 16, 2015 — Hyperion Therapeutics, Inc. (Nasdaq:HPTX) (“Hyperion”) today announced that it has amicably resolved its disputes, and entered into a completion of phase III cl |
|
| February 13, 2015 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* Hyperion Therapeutics, Inc. (Name of Issuer) Common Stock, $0.0001 par value (Title of Class of Securities) 44915N 101 (CUSIP Number) December 31, 2014 Date of Event Which Requires Filing of the Statement Check the appropriate box to designate the rule p |
|
| February 12, 2015 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 3 )* Hyperion Therapeutics, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 44915N101 (CUSIP Number) December 31, 2014 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which |
|
| February 10, 2015 |
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 9, 2015 HYPERION THERAPEUTICS, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-35614 61-1512713 (State or Other Jurisdiction of Incorporation) ( |
|
| January 21, 2015 |
HPTX / Hyperion Therapeutics Inc S-8 - - S-8 S-8 As filed with the Securities and Exchange Commission on January 21, 2015 Registration No. |
|
| December 10, 2014 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* Hyperion Therapeutics, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 44915N101 (CUSIP Number) November 28, 2014 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which |
|
| November 6, 2014 |
Hyperion Therapeutics Announces Third Quarter 2014 Financial Results EXHIBIT 99.1 Hyperion Therapeutics Announces Third Quarter 2014 Financial Results - UCD Product Portfolio Generates $26.2 Million in Net Sales During the Quarter - - Company Delivers Fifth Consecutive Quarter of Adjusted Net Income - - Company to Host Conference Call Today at 4:05 p.m. ET (1:05 p.m. PT) - BRISBANE, Calif., Nov. 6, 2014 (GLOBE NEWSWIRE) - Hyperion Therapeutics, Inc. (Nasdaq:HPTX) t |
|
| November 6, 2014 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event Reported): November 6, 2014 HYPERION THERAPEUTICS, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-35614 61-1512713 (State or Other Jurisdiction of Incorporation) (Commissio |
|
| September 8, 2014 |
Financial Statements and Exhibits, Material Impairments, Other Events Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 7, 2014 HYPERION THERAPEUTICS, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-35614 61-1512713 (State or Other Jurisdiction of Incorporation) |
|
| September 8, 2014 |
EX-99.1 Exhibit 99.1 CONTACT: Myesha Edwards Corporate Communications and Investor Relations (650) 745-7829 Carolyn Wang WCG (415) 225-5050 Hyperion Therapeutics Terminates DiaPep277® Program Company Discovers Serious Misconduct by Andromeda Biotech Ltd. Company to Host Conference Call Today at 9:00 a.m. ET (6:00 a.m. PT) Brisbane, Calif. – September 8, 2014 – Hyperion Therapeutics, Inc. (NASDAQ: |
|
| August 18, 2014 |
HPTX / Hyperion Therapeutics Inc 144 - - 144 1 hyperion144.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933 ATTENTION: Transmit for filing 3 copies of this form concurrently with either placing an order with a broker to execute sale or executing a sale directly with a market maker. 1 (a) NAME OF ISSUER (Please t |
|
| August 12, 2014 |
Hyperion Therapeutics Appoints Theodore Schroeder to Board of Directors EXHIBIT 99.1 Hyperion Therapeutics Appoints Theodore Schroeder to Board of Directors BRISBANE, Calif., Aug. 12, 2014 (GLOBE NEWSWIRE) - Hyperion Therapeutics, Inc. (Nasdaq:HPTX) today announced the appointment of Theodore "Ted" Schroeder to its board of directors effective August 11, 2014. Mr. Schroeder has over two decades of experience in the life sciences industry. Most recently, he was the fou |
|
| August 12, 2014 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event Reported): August 12, 2014 HYPERION THERAPEUTICS, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-35614 61-1512713 (State or Other Jurisdiction of Incorporation) (Commission |
|
| August 7, 2014 |
Hyperion Therapeutics Announces Second Quarter 2014 Financial Results EXHIBIT 99.1 Hyperion Therapeutics Announces Second Quarter 2014 Financial Results UCD Product Portfolio Generates $37.1 Million in Net Sales During the Quarter -$31.6 million of RAVICTI® recognized in the quarter including $11.7 million of previously deferred revenue -Adjusted net income of $21.1 million earned in quarter Company to Host Conference Call Today at 4:30 p.m. ET (1:30 p.m. PT) BRISBA |
|
| August 7, 2014 |
Hyperion Therapeutics, Inc. Unaudited Pro Forma Condensed Combined Financial Statements EX-99.2 Exhibit 99.2 Hyperion Therapeutics, Inc. Unaudited Pro Forma Condensed Combined Financial Statements On June 12, 2014, Hyperion Therapeutics, Inc. a Delaware corporation (“Hyperion” or the “Company”), and Hyperion Therapeutics Israel Holding Corp, Ltd., a wholly-owned subsidiary of the Company, completed the purchase of all of the outstanding ordinary shares of Andromeda Biotech Ltd (“Andr |
|
| August 7, 2014 |
Andromeda Biotech Ltd. (A Development Stage Company) Financial Statements As of December 31, 2013 EX-99.1 3 d767400dex991.htm EX-99.1 Exhibit 99.1 Andromeda Biotech Ltd. (A Development Stage Company) Financial Statements As of December 31, 2013 Andromeda Biotech Ltd. (A Development Stage Company) Financial Statements as at December 31, 2013 Contents Page Independent Auditor’s Report 2-3 Balance Sheets 4 Statements of Operations 5 Statements of Comprehensive Loss 6 Statements of Changes in Shar |
|
| August 7, 2014 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event Reported): August 7, 2014 HYPERION THERAPEUTICS, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-35614 61-1512713 (State or Other Jurisdiction of Incorporation) (Commission |
|
| August 7, 2014 |
Financial Statements and Exhibits 8-K/A 1 d767400d8ka.htm FORM 8-K/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 13, 2014 HYPERION THERAPEUTICS, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-35614 61-1512713 (State or Other Jurisdi |
|
| July 21, 2014 |
EX-10.1 Exhibit 10.1 LOAN AND SECURITY AGREEMENT THIS LOAN AND SECURITY AGREEMENT (this “Agreement”) dated as of July 18, 2014 (the “Effective Date”) between SILICON VALLEY BANK, a California corporation (“Bank”), and HYPERION THERAPEUTICS, INC., a Delaware corporation (“Borrower”) provides the terms on which Bank shall lend to Borrower and Borrower shall repay Bank. The parties agree as follows: |
|
| July 21, 2014 |
8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 18, 2014 HYPERION THERAPEUTICS, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-35614 61-1512713 (State or Other Jurisdiction of Incorporation) (Commissi |
|
| July 8, 2014 |
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 8, 2014 HYPERION THERAPEUTICS, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-35614 61-1512713 (State or Other Jurisdiction of Incorporation) (Comm |
|
| June 13, 2014 |
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 12, 2014 HYPERION THERAPEUTICS, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-35614 61-1512713 (State or Other Jurisdiction of Incorporation) (Com |
|
| June 13, 2014 |
EX-99.1 Exhibit 99.1 CONTACT: Myesha Edwards Corporate Communications and Investor Relations (650) 745-7829 Hyperion Therapeutics Completes Acquisition of Andromeda Biotech, Ltd. - Hyperion’s Orphan Drug Pipeline Now Includes DiaPep277®, A First-in-Class Immunotherapy for New Onset Type 1 Diabetes, with Phase 3 Data Expected in the First Quarter of 2015 - Brisbane, Calif. – June 12, 2014 – Hyperio |
|
| June 9, 2014 |
HPTX / Hyperion Therapeutics Inc / SOFINNOVA VENTURE PARTNERS VII L P - SC 13D/A Activist Investment SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13D (RULE 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(a) (Amendment No. 4)* Hyperion Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 44915N101 (CUSIP Number) Nathalie Auber Sofinnova |
|
| June 6, 2014 |
Regulation FD Disclosure - FORM 8-K Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 4, 2014 HYPERION THERAPEUTICS, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-35614 61-1512713 (State or Other Jurisdiction of Incorporation) (Comm |
|
| May 28, 2014 |
Submission of Matters to a Vote of Security Holders Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 27, 2014 HYPERION THERAPEUTICS, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-35614 61-1512713 (State or Other Jurisdiction of Incorporation) (Comm |
|
| May 6, 2014 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event Reported): May 6, 2014 HYPERION THERAPEUTICS, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-35614 61-1512713 (State or Other Jurisdiction of Incorporation) (Commission Fil |
|
| May 6, 2014 |
Hyperion Therapeutics Announces First Quarter 2014 Financial Results EXHIBIT 99.1 Hyperion Therapeutics Announces First Quarter 2014 Financial Results - Company signs definitive agreement to expand its pipeline - - Company to Host Conference Call Today at 4:30 p.m. ET (1:30 p.m. PT) - BRISBANE, Calif., May 6, 2014 (GLOBE NEWSWIRE) - Hyperion Therapeutics, Inc. (Nasdaq:HPTX) today reported net revenue of $19.5 million for the first quarter of 2014 from the sales of |
|
| April 24, 2014 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event Reported): April 23, 2014 HYPERION THERAPEUTICS, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-35614 61-1512713 (State or Other Jurisdiction of Incorporation) (Commission |
|
| April 24, 2014 |
Hyperion Therapeutics to Broaden Orphan Disease Pipeline With Acquisition of Andromeda Biotech Ltd. EXHIBIT 99.1 Hyperion Therapeutics to Broaden Orphan Disease Pipeline With Acquisition of Andromeda Biotech Ltd. -DiaPep277®, a First-in-Class Immune Intervention Therapy in Phase 3 Testing for New Onset Type 1 Diabetes- -Hyperion to Host Analyst/Investor Teleconference Today at 8:45 a.m. EDT (5:45 a.m. PDT)- BRISBANE, Calif., April 24, 2014 (GLOBE NEWSWIRE) - Hyperion Therapeutics (Nasdaq:HPTX) a |
|
| April 21, 2014 |
DEF 14A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| March 18, 2014 |
Prepared by R.R. Donnelley Financial - Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 17, 2014 HYPERION THERAPEUTICS, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-35614 61-1512713 (State or O |
|
| March 11, 2014 |
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 10, 2014 HYPERION THERAPEUTICS, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-35614 61-1512713 (State or Other Jurisdiction of Incorporation) (Co |
|
| March 7, 2014 |
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 5, 2014 HYPERION THERAPEUTICS, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-35614 61-1512713 (State or Other Jurisdiction of Incorporation) (Com |
|
| March 7, 2014 |
HPTX FORM 10-K (Annual Report) Form 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2013 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-35614 HYPERION THERAPEUTICS, INC. |
|
| March 6, 2014 |
HPTX / Hyperion Therapeutics Inc / SOFINNOVA VENTURE PARTNERS VII L P - SC 13D/A Activist Investment CUSIP NO. 44915N101 13D Page 1 of 9 SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13D (RULE 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(a) (Amendment No. 3)* Hyperion Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 44915N101 (CU |
|
| February 27, 2014 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event Reported): February 27, 2014 HYPERION THERAPEUTICS, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-35614 61-1512713 (State or Other Jurisdiction of Incorporation) (Commissi |
|
| February 27, 2014 |
Hyperion Therapeutics Announces Fourth Quarter and Full Year 2013 Financial Results EXHIBIT 99.1 Hyperion Therapeutics Announces Fourth Quarter and Full Year 2013 Financial Results Total 2013 Net Revenue of $42.2 Million; Fourth Quarter Net Sales of $18.6 Million, Including 46 Percent Growth in RAVICTI Sales BRISBANE, Calif., Feb. 27, 2014 (GLOBE NEWSWIRE) - Hyperion Therapeutics, Inc. (Nasdaq:HPTX) today reported net revenue of $18.6 million and $42.2 million for the fourth quar |
|
| February 25, 2014 |
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 21, 2014 HYPERION THERAPEUTICS, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-35614 61-1512713 (State or Other Jurisdiction of Incorporation) |
|
| February 14, 2014 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Hyperion Therapeutics, Inc. (Name of Issuer) Common Stock, $0.0001 par value (Title of Class of Securities) 44915N 101 (CUSIP Number) December 31, 2013 Date of Event Which Requires Filing of the Statement Check the appropriate box to designate the rule p |
|
| February 14, 2014 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Hyperion Therapeutics, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 44915N101 (CUSIP Number) December 31, 2013 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which |
|
| February 14, 2014 |
HPTX / Hyperion Therapeutics Inc / RA Capital Management, LLC - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Hyperion Therapeutics, Inc. (Name of Issuer) Common Stock, $0.0001 par value (Title of Class of Securities) 44915N101 (CUSIP Number) December 31, 2013 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule |
|
| January 31, 2014 |
Form S-8 As filed with the Securities and Exchange Commission on January 31, 2014 Registration No. |
|
| January 30, 2014 |
HPTX / Hyperion Therapeutics Inc / SOFINNOVA VENTURE PARTNERS VII L P - SC 13D/A Activist Investment CUSIP NO. 44915N101 13D Page 1 of 11 SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13D (RULE 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(a) (Amendment No. 2)* Hyperion Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 44915N101 (C |
|
| December 24, 2013 |
HPTX / Hyperion Therapeutics Inc / SOFINNOVA VENTURE PARTNERS VII L P - SC 13D/A Activist Investment CUSIP NO. 44915N101 13D Page 1 of 9 SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13D (RULE 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(a) (Amendment No. 1)* Hyperion Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 44915N101 (CU |
|
| November 12, 2013 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event Reported): November 12, 2013 HYPERION THERAPEUTICS, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-35614 61-1512713 (State or Other Jurisdiction of Incorporation) (Commissi |
|
| November 12, 2013 |
Hyperion Therapeutics Announces Third Quarter 2013 Financial Results EXHIBIT 99.1 Hyperion Therapeutics Announces Third Quarter 2013 Financial Results UCD Product Portfolio Generates $15.5 Million in Net Sales During the Quarter Including 58 Percent Growth in RAVICTI Sales SOUTH SAN FRANCISCO, Calif., Nov. 12, 2013 (GLOBE NEWSWIRE) - Hyperion Therapeutics, Inc. (Nasdaq:HPTX) today reported net revenue of $15.5 million during the third quarter of 2013 which includes |
|
| October 16, 2013 |
EX-10.1 Exhibit 10.1 OFFICE LEASE by and between 2000 SIERRA POINT PARKWAY LLC, a Delaware limited liability company, as Landlord and HYPERION THERAPEUTICS, INC., a Delaware corporation as Tenant 2000 Sierra Point Parkway Brisbane, California 94065 October 14, 2013 OFFICE LEASE THIS LEASE is entered into as of October 14, 2013 (the “Effective Date”), by and between 2000 SIERRA POINT PARKWAY LLC, a |
|
| October 16, 2013 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits - FORM 8-K Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 14, 2013 HYPERION THERAPEUTICS, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-35614 61-1512713 (State or Other Jurisdiction of Incorporation) ( |
|
| September 10, 2013 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Hyperion Therapeutics, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 44915N101 (CUSIP Number) August 31, 2013 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which thi |
|
| August 14, 2013 |
EX-1.1 Exhibit 1.1 EXECUTION VERSION HYPERION THERAPEUTICS, INC. Up to $50,000,000 of Shares of Common Stock (par value $0.0001 per share) Controlled Equity OfferingSM Sales Agreement August 14, 2013 Cantor Fitzgerald & Co. 499 Park Avenue New York, NY 10022 Ladies and Gentlemen: Hyperion Therapeutics, Inc., a Delaware corporation (the “Company”), confirms its agreement (this “Agreement”) with Can |
|
| August 14, 2013 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event Reported): August 14, 2013 HYPERION THERAPEUTICS, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-35614 61-1512713 (State or Other Jurisdiction of Incorporation) (Commission |
|
| August 14, 2013 |
EX-4.7 Exhibit 4.7 HYPERION THERAPEUTICS, INC. as Issuer, and , as Trustee INDENTURE Dated as of , 201 Senior Debt Securities Reconciliation and tie between Trust Indenture Act of 1939 and Indenture, dated as of December 7, 2007 Trust Indenture Act Section Indenture Section § 310(a)(1) 6.9 (a)(2) 6.9 (a)(3) Not Applicable (a)(4) Not Applicable (a)(5) 6.9 (b) 6.8, 6.10 § 311(a) 6.13(a) (b) 6.13(b) |
|
| August 14, 2013 |
Hyperion Therapeutics Announces Second Quarter 2013 Financial Results EXHIBIT 99.1 Hyperion Therapeutics Announces Second Quarter 2013 Financial Results Strong Early Launch Progress With Company's First Product, RAVICTI(R); Completed Integration of Acquired Product, BUPHENYL(R) SOUTH SAN FRANCISCO, Calif., Aug. 14, 2013 (GLOBE NEWSWIRE) - Hyperion Therapeutics, Inc. (Nasdaq:HPTX) today reported net revenue of $7.3 million following the first full quarter of sales of |
|
| August 14, 2013 |
STATEMENT REGARDING COMPUTATION OF RATIO OF EARNINGS TO FIXED CHARGES (in thousands, except ratios) EX-12.1 Exhibit 12.1 STATEMENT REGARDING COMPUTATION OF RATIO OF EARNINGS TO FIXED CHARGES (in thousands, except ratios) The following table sets forth our ratio of earnings to fixed charges for the six months ended June 30, 2013, and for the years ended December 31, 2012, 2011, 2010, 2009 and 2008. As the ratios of earnings to fixed charges indicate less than one-to-one coverage in each of the ye |
|
| August 14, 2013 |
Form S-3 Table of Contents As filed with the Securities and Exchange Commission on August 14, 2013 Registration No. |
|
| August 12, 2013 |
Exhibit 99.2 Hyperion Therapeutics, Inc. and BUPHENYL Product Line Unaudited Pro Forma Condensed Combined Financial Statements On May 31, 2013, Hyperion Therapeutics, Inc. (“Hyperion”) completed its acquisition of BUPHENYL® (sodium phenylbutyrate) Tablets and Powder, an FDA-approved therapy for treatment of the most prevalent urea cycle disorders (“UCD”), from Ucyclyd Pharma, Inc. (“Ucyclyd”), a w |
|
| August 12, 2013 |
Exhibit 99.1 FINANCIAL STATEMENTS BUPHENYL® Product Line (a component of Ucyclyd Pharma Inc.) For the Period From December 11, 2012 Through December 31, 2012, the Period From January 1, 2012 Through December 10, 2012, the Year Ended December 31, 2011, the Three Months Ended March 31, 2013 (unaudited), and the Three Months Ended March 31, 2012 (unaudited) With Reports of Independent Auditors BUPHEN |
|
| August 12, 2013 |
Financial Statements and Exhibits - 8-K/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 29, 2013 HYPERION THERAPEUTICS, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-35614 61-1512713 (State or Other Jurisdiction of Incorporation) (Commission |
|
| July 22, 2013 |
SC 13D/A 1 d571323dsc13da.htm AMENDMENT NO. 1 TO SCHEDULE 13D UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 1)* Hyperion Therapeutics, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 44915N 101 (CUSIP Number) Judy Koh Chief Financial Officer Bay City Capital LLC 750 Battery Street, Sui |
|
| June 3, 2013 |
HYPERION THERAPEUTICS ACQUIRES WORLDWIDE RIGHTS TO BUPHENYL EX-99.1 Exhibit 99.1 CONTACT: Sylvia Wheeler Vice President, Investor Relations (650) 745-7834 [email protected] HYPERION THERAPEUTICS ACQUIRES WORLDWIDE RIGHTS TO BUPHENYL SOUTH SAN FRANCISCO, Calif., June 3, 2013 — Hyperion Therapeutics, Inc. (NasdaqGM: HPTX) today announced the completion of its acquisition of BUPHENYL® (sodium phenylbutyrate) Tablets and Powder, an FDA-approved the |
|
| June 3, 2013 |
8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 29, 2013 HYPERION THERAPEUTICS, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-35614 61-1512713 (State or Other Jurisdiction of Incorporation) (Commissio |
|
| May 17, 2013 |
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 17, 2013 HYPERION THERAPEUTICS, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-35614 61-1512713 (State or Other Jurisdiction of Incorporation) (Comm |
|
| May 16, 2013 |
Hyperion Therapeutics Added to Nasdaq Biotechnology Index (NBI) EX-99.1 Exhibit 99.1 Contact: Jeffrey Farrow CFO Hyperion Therapeutics (650) 745-7816 Hyperion Therapeutics Added to Nasdaq Biotechnology Index (NBI) SOUTH SAN FRANCISCO, Calif., May16, 2013 — Hyperion Therapeutics, Inc. (NasdaqGM: HPTX) today announced that it has been selected for addition to the Nasdaq Biotechnology Index® (Nasdaq:NBI). The semi-annual re-ranking of the NASDAQ Biotechnology Ind |
|
| May 16, 2013 |
Financial Statements and Exhibits, Other Events Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 16, 2013 HYPERION THERAPEUTICS, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-35614 61-1512713 (State or Other Jurisdiction of Incorporation) (Comm |
|
| May 9, 2013 |
EX-99.1 Exhibit 99.1 CONTACTS: Jeffrey Farrow, CFO Kristie Kuhl, Media Relations (650) 745-7816 (203) 556-7417 [email protected] [email protected] Hyperion Therapeutics Announces First Quarter 2013 Operating Results First Net Sales of RAVICTI Post-approval Reported at $0.8 Million Strong Cash Position of $102.7 million South San Francisco, CA – May 9, 2013 – Hyperion Therapeutics, Inc. ( |
|
| May 9, 2013 |
Financial Statements and Exhibits, Results of Operations and Financial Condition Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 9, 2013 HYPERION THERAPEUTICS, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-35614 61-1512713 (State or Other Jurisdiction of Incorporation) (Commi |
|
| April 30, 2013 |
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 29, 2013 HYPERION THERAPEUTICS, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-35614 61-1512713 (State or Other Jurisdiction of Incorporation) (Co |
|
| April 23, 2013 |
Form S-8 As filed with the Securities and Exchange Commission on April 23, 2013 Registration No. |
|
| April 22, 2013 |
Definitive Proxy Statement Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| April 11, 2013 |
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 8, 2013 HYPERION THERAPEUTICS, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-35614 61-1512713 (State or Other Jurisdiction of Incorporation) (Com |
|
| March 8, 2013 |
Prospectus Supplement Filed Pursuant to Rule 424(b)(4) Table of Contents Filed Pursuant to Rule 424(b)(4) Registration No. |
|
| March 7, 2013 |
S-1MEF As filed with the Securities and Exchange Commission on March 7, 2013 Registration Statement File No. |
|
| March 5, 2013 |
Acceleration Request by the Underwriters March 5, 2013 VIA EDGAR AND FACSIMILE United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N. |
|
| March 5, 2013 |
EX-1.1 Exhibit 1.1 HYPERION THERAPEUTICS, INC. (a Delaware corporation) [ ] Shares of Common Stock UNDERWRITING AGREEMENT Dated: [ ], 2013 Hyperion Therapeutics, Inc. (a Delaware corporation) [ ] Shares of Common Stock ($0.0001 Par Value Per Share) UNDERWRITING AGREEMENT [ ], 2013 Leerink Swann LLC Cowen and Company, LLC As Representatives of the Several Underwriters c/o Leerink Swann LLC One Fede |
|
| March 5, 2013 |
Acceleration Request by the Company HYPERION THERAPEUTICS, INC. 601 Gateway Boulevard, Suite 200 South San Francisco, CA 94080 March 5, 2013 VIA EDGAR Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549 Attn: Jeffrey Riedler Re: Hyperion Therapeutics, Inc. Registration Statement on Form S-1 (File No. 333-186880) Request for Acceleration of Effective Date Dear Mr. Riedler: |
|
| March 5, 2013 |
Amendment No. 1 to Form S-1 Table of Contents As filed with the Securities and Exchange Commission on March 5, 2013 Registration Statement File No. 333-186880 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Amendment No. 1 to Form S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 HYPERION THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) De |
|
| March 4, 2013 |
HPTX / Hyperion Therapeutics Inc / RA CAPITAL MANAGEMENT, L.P. - SC 13G Passive Investment SC 13G 1 v336979sc13g.htm SC 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No.)* Hyperion Therapeutics, Inc. (Name of Issuer) Common Stock, $0.0001 par value (Title of Class of Securities) 44915N101 (CUSIP Number) February 28, 2013 (Date of Event Which Requires Filing of this Statement) Check the approp |
|
| February 26, 2013 |
Registration Statement - FORM S-1 Form S-1 Table of Contents As filed with the Securities and Exchange Commission on February 26, 2013 Registration Statement File No. |
|
| February 25, 2013 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 25, 2013 HYPERION THERAPEUTICS, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-35614 61-1512713 (State or Other Jurisdiction of Incorporation) (Commissi |
|
| February 25, 2013 |
Hyperion Therapeutics Announces Fourth Quarter and Full Year 2012 Operating Results EX-99.1 Exhibit 99.1 Contact: Shari Annes, Investor Relations 650-888-0902 [email protected] Hyperion Therapeutics Announces Fourth Quarter and Full Year 2012 Operating Results South San Francisco, CA – February 25, 2013 – Hyperion Therapeutics, Inc. (Nasdaq GM: HPTX) today reported financial operating results for the fourth quarter and the year ended December 31, 2012. According to Chief |
|
| February 25, 2013 |
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 19, 2013 HYPERION THERAPEUTICS, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-35614 61-1512713 (State or Other Jurisdiction of Incorporation) |
|
| February 20, 2013 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 14, 2013 HYPERION THERAPEUTICS, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-35614 61-1512713 (State or Other Jurisdiction of Incorporation) (Commissi |
|
| February 20, 2013 |
DISTRIBUTION SERVICES AGREEMENT EX-10.1 Exhibit 10.1 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24(B)(2) OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. DISTRIBUTION SERVICES AGREEMENT This Distribution Services Agreement (this “Agreement”) dated as of February 14, 2013 (the “Effective Date |
|
| February 1, 2013 |
Financial Statements and Exhibits, Other Events - FORM 8-K Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 1, 2013 HYPERION THERAPEUTICS, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-35614 61-1512713 (State or Other Jurisdiction of Incorporation) ( |
|
| February 1, 2013 |
Risk Factors Exhibit 99.2 RISK FACTORS An investment in our common stock involves a high degree of risk. We operate in a dynamic and rapidly changing industry that involves numerous risks and uncertainties. The risks and uncertainties described below are not the only ones we face. Other risks and uncertainties, including those that we do not currently consider material, may impair our business. If |
|
| February 1, 2013 |
Press Release Exhibit 99.1 CONTACTS: Myesha Edwards, Investor Relations (650) 745-7829 [email protected] Kristie Kuhl, Media Relations (203) 556-7417 [email protected] Hyperion Therapeutics’ RAVICTI™ (glycerol phenylbutyrate) Liquid Receives FDA Approval for Treatment of Urea Cycle Disorders • Anticipated market launch by end of April 2013 • Patent allowance extends coverage to 2032 S |
|
| January 22, 2013 |
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 22, 2013 HYPERION THERAPEUTICS, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-35614 61-1512713 (State or Other Jurisdiction of Incorporation) ( |
|
| January 16, 2013 |
Hyperion Notified that FDA Will Not Meet the PDUFA Action Date for Ravicti™ Press Release Exhibit 99.1 Hyperion Notified that FDA Will Not Meet the PDUFA Action Date for Ravicti™ South San Francisco, CA – January 16, 2013 – Hyperion Therapeutics, Inc. (Nasdaq GM:HPTX) said that the U.S. Food and Drug Administration (FDA) has advised the Company not to expect a final action by the Prescription Drug User Fee Act (PDUFA) action date of January 23, 2013. The agency explained |
|
| January 16, 2013 |
Financial Statements and Exhibits, Other Events - FORM 8-K Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 15, 2013 HYPERION THERAPEUTICS, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-35614 61-1512713 (State or Other Jurisdiction of Incorporation) ( |
|
| December 4, 2012 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits - FORM 8-K Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 30, 2012 HYPERION THERAPEUTICS, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-35614 61-1512713 (State or Other Jurisdiction of Incorporation) |
|
| December 4, 2012 |
601 GATEWAY BOULEVARD SECOND AMENDMENT TO OFFICE LEASE Second Amendment to Office Lease by and between the Company and Gateway Center Exhibit 10. |
|
| November 8, 2012 |
Financial Statements and Exhibits, Results of Operations and Financial Condition 8-K 1 d434876d8k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 7, 2012 HYPERION THERAPEUTICS, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-35614 61-1512713 (State or Other Jurisdictio |
|
| November 8, 2012 |
Hyperion Therapeutics Announces Third Quarter 2012 Operating Results Press Release Exhibit 99.1 Hyperion Therapeutics Announces Third Quarter 2012 Operating Results South San Francisco, CA – November 7, 2012 – Hyperion Therapeutics, Inc. (NasdaqGM: HPTX) today reported consolidated financial results for the third quarter of 2012. According to Chief Executive Officer, Donald J. Santel, “The past several months have been an exciting time for Hyperion. As we move clos |
|
| October 18, 2012 |
Form S-8 As filed with the Securities and Exchange Commission on October 18, 2012 Registration No. |
|
| September 28, 2012 |
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 26, 2012 HYPERION THERAPEUTICS, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-35614 61-1512713 (State or Other Jurisdiction of Incorporation) |
|
| September 6, 2012 |
Financial Statements and Exhibits, Other Events - FORM 8-K Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 5, 2012 HYPERION THERAPEUTICS, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-35614 61-1512713 (State or Other Jurisdiction of Incorporation) |
|
| September 6, 2012 |
Hyperion Therapeutics Announces Second Quarter 2012 Operating Results Press Release Exhibit 99.1 Hyperion Therapeutics Announces Second Quarter 2012 Operating Results South San Francisco, CA – September 6, 2012 – Hyperion Therapeutics, Inc. (NasdaqGM: HPTX) today reported consolidated financial results for the second quarter of 2012. The company reported cash and cash equivalents of $7.3 million as of June 30, 2012. Subsequent to the end of the quarter, on July 31, |
|
| September 6, 2012 |
Hyperion Therapeutics Announces Extension of Action Date for Ravicti™ NDA to January 23, 2013 EX-99.1 2 d407379dex991.htm PRESS RELEASE Exhibit 99.1 Hyperion Therapeutics Announces Extension of Action Date for Ravicti™ NDA to January 23, 2013 — Extension to enable FDA to review additional solicited analyses of existing clinical information provided by the company — South San Francisco, CA –Sept 5, 2012— Hyperion Therapeutics, Inc. (NasdaqGM:HPTX) announced today that it has received a comm |
|
| September 6, 2012 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 6, 2012 HYPERION THERAPEUTICS, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-35614 61-1512713 (State or Other Jurisdiction of Incorporation) (Commissi |
|
| August 28, 2012 |
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 23, 2012 HYPERION THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-35614 61-1512713 (state or other jurisdiction of incorporation |
|
| August 10, 2012 |
HPTX / Hyperion Therapeutics Inc / Highland Management Partners VII, LLC - SC 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) Information Statement Pursuant to Rules 13d-1 and 13d-2 Under the Securities Exchange Act of 1934 (Amendment No. )* Hyperion Therapeutics, Inc. (Name of Issuer) Common Stock, $0.0001 par value (Title of Class of Securities) 44915N 101 (CUSIP Number) July 31, 2012 Date of Event Which Requires Filing |
|
| August 7, 2012 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. )* Hyperion Therapeutics, Inc. (Name of Issuer) Common Stock, $.0001 par value (Title of Class of Securities) 44915N101 (CUSIP Number) Louis S. Citron, Esq. New Enterprise Associates 1954 Greenspring Drive, Suite 600 Timonium, MD 21093 (410) 842-4000 (Name, |
|
| August 6, 2012 |
CUSIP NO. 44915N101 13D Page 1 of 14 SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13D (RULE 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(a) (Amendment No. )* Hyperion Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 44915N101 (CU |
|
| August 2, 2012 |
HPTX / Hyperion Therapeutics Inc / BAY CITY CAPITAL LLC - SCHEDULE 13D Activist Investment SC 13D 1 d390939dsc13d.htm SCHEDULE 13D UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. )* Hyperion Therapeutics, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 44915N 101 (CUSIP Number) Judy Koh Chief Financial Officer Bay City Capital LLC 750 Battery Street, Suite 400 San Francisco, C |
|
| August 2, 2012 |
EX-99.7.1 2 d390939dex9971.htm JOINT FILING AGREEMENT Exhibit 7.1 JOINT FILING AGREEMENT Each of Bay City Capital LLC, Bay City Capital Management V LLC, Bay City Capital Fund V, L.P. and Bay City Capital Fund V Co-Investment Fund, L.P. hereby express its agreement that the attached Schedule 13D (and any amendments thereto) relating to the common stock of Hyperion Therapeutics, Inc. is filed on be |
|
| July 31, 2012 |
HYPERION THERAPEUTICS, INC. AMENDED AND RESTATED CERTIFICATE OF INCORPORATION Amended and Restated Certificate of Incorporation Exhibit 3.1 HYPERION THERAPEUTICS, INC. AMENDED AND RESTATED CERTIFICATE OF INCORPORATION Hyperion Therapeutics, Inc., a Delaware Corporation, (the “Corporation”) hereby certifies as follows. 1. The name of the Corporation is Hyperion Therapeutics, Inc. The Certificate of Incorporation was originally filed with the Secretary of State on November 1, |
|
| July 31, 2012 |
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 31, 2012 HYPERION THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-35614 61-1512713 (state or other jurisdiction of incorporation) |
|
| July 27, 2012 |
424B4 1 d178027d424b4.htm PROSPECTUS FILED PURSUANT TO RULE 424(B)(4) Table of Contents Filed Pursuant to Rule 424(b)(4) Registration Nos. 333-180694 and 333-182850 PROSPECTUS 5,000,000 Shares Common Stock Hyperion Therapeutics, Inc. is offering 5,000,000 shares of common stock. This is our initial public offering, and no public market currently exists for our common stock. The initial public offe |
|
| July 25, 2012 |
- FILED PURSUANT TO RULE 462(B) Filed Pursuant to Rule 462(b) As filed with the Securities and Exchange Commission on July 25, 2012 Registration Statement File No. |
|
| July 25, 2012 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-A FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES PURSUANT TO SECTION 12(b) OR 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 HYPERION THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 61-1512713 (State of Incorporation or Organization) (I.R.S. Employer Identification No.) 601 Gateway Bo |
|
| July 24, 2012 |
Acceleration Request HYPERION THERAPEUTICS, INC. 601 Gateway Boulevard, Suite 200 South San Francisco, CA 94080 July 24, 2012 VIA EDGAR AND FACSIMILE Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549 Attn: Jeffrey Riedler Re: Hyperion Therapeutics, Inc. Registration Statement on Form S-1 (File No. 333-180694) Request for Acceleration of Effective Date Dear Mr. Riedler: P |
|
| July 24, 2012 |
Acceleration Request July 24, 2012 VIA EDGAR AND FACSIMILE United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N. |
|
| July 13, 2012 |
Amended and Restated Warrant issued pursuant to the Loan and Security Agreement Exhibit 4. |
|
| July 13, 2012 |
AMENDED AND RESTATED CERTIFICATE OF INCORPORATION HYPERION THERAPEUTICS, INC. Exhibit 3.1 AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF HYPERION THERAPEUTICS, INC. Hyperion Therapeutics, Inc., a corporation organized and existing under and by virtue of the Delaware General Corporation Law, hereby certifies as follows: 1. The name of this corporation is Hyperion Therapeutics, Inc. and the date of filing of the original Certificate of Incorporation of this corporation |
|
| July 13, 2012 |
Amendment No. 4 to Form S-1 Table of Contents As filed with the Securities and Exchange Commission on July 13, 2012 Registration Statement File No. 333-180694 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Amendment No. 4 to Form S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 HYPERION THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) De |
|
| July 12, 2012 |
SEC Correspondence Hogan Lovells US LLP Columbia Square 555 Thirteenth Street, NW Washington, DC 20004 T +1 202 637 5600 F +1 202 637 5910 www. |
|
| July 11, 2012 |
SEC Correspondence Hogan Lovells US LLP Columbia Square 555 Thirteenth Street, NW Washington, DC 20004 T +1 202 637 5600 F +1 202 637 5910 www. |
|
| July 10, 2012 |
Correspondence with the SEC Hogan Lovells US LLP Columbia Square 555 Thirteenth Street, NW Washington, DC 20004 T +1 202 637 5600 F +1 202 637 5910 www. |
|
| July 10, 2012 |
Correspondence with the SEC Hogan Lovells US LLP Columbia Square 555 Thirteenth Street, NW Washington, DC 20004 T +1 202 637 5600 F +1 202 637 5910 www. |
|
| July 9, 2012 |
Correspondence with the SEC Hogan Lovells US LLP Columbia Square 555 Thirteenth Street, NW Washington, DC 20004 T +1 202 637 5600 F +1 202 637 5910 www. |
|
| July 5, 2012 |
Specimen Common Stock Certificate of the Company Exhibit 4.1 The following abbreviations, when used in the inscription on the face of this certificate, shall be construed as though they were written out in full according to applicable laws or regulations: TEN COM - as tenants in common UNIF GIFT MIN ACT - ................. Custodian ................. TEN ENT - as tenants by the entireties (Cust) ( |
|
| July 5, 2012 |
Response Letter to the SEC Hogan Lovells US LLP 525 University Avenue 4th Floor Palo Alto, CA 94301 T +1 650 463 4000 F +1 650 463 4199 www. |
|
| July 5, 2012 |
Amendment No. 3 to Form S-1 Table of Contents As filed with the Securities and Exchange Commission on July 5, 2012 Registration Statement File No. 333-180694 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Amendment No. 3 to Form S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 HYPERION THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Del |
|
| July 3, 2012 |
Hogan Lovells US LLP Columbia Square 555 Thirteenth Street, NW Washington, DC 20004 T +1 202 637 5600 F +1 202 637 5910 www. |
|
| June 18, 2012 |
Amendment No. 2 to Form S-1 Table of Contents As filed with the Securities and Exchange Commission on June 18, 2012 Registration Statement File No. 333-180694 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Amendment No. 2 to Form S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 HYPERION THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) De |
|
| June 18, 2012 |
Response Letter to the SEC Hogan Lovells US LLP Columbia Square 555 Thirteenth Street, NW Washington, DC 20004 T +1 202 637 5600 F +1 202 637 5910 www. |
|
| June 18, 2012 |
Underwriting Agreement Exhibit 1.1 HYPERION THERAPEUTICS, INC. (a Delaware corporation) [ ] Shares of Common Stock UNDERWRITING AGREEMENT Dated: , 2012 Hyperion Therapeutics, Inc. (a Delaware corporation) [ ] Shares of Common Stock ($0.0001 Par Value Per Share) UNDERWRITING AGREEMENT , 2012 Leerink Swann LLC Cowen and Company, LLC As Representatives of the Several Underwriters c/o Leerink Swann LL |
|
| May 24, 2012 |
HYPERION THERAPEUTICS, INC. 2012 OMNIBUS INCENTIVE PLAN NON-QUALIFIED OPTION AGREEMENT Form of Nonstatutory Option Agreement Exhibit 10.17 HYPERION THERAPEUTICS, INC. 2012 OMNIBUS INCENTIVE PLAN NON-QUALIFIED OPTION AGREEMENT Hyperion Therapeutics, Inc., a Delaware corporation (the “Company”), hereby grants an option to purchase shares of its common stock, par value $ per share (the “Option”), to the optionee named below, subject to the vesting and other conditions set forth below. |
|
| May 24, 2012 |
FORM OF WARRANT TO PURCHASE STOCK Exhibit 4.9 THIS WARRANT AND THE SHARES ISSUABLE HEREUNDER HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”), OR THE SECURITIES LAWS OF ANY STATE AND, EXCEPT AS SET FORTH IN SECTIONS 5.3 AND 5.4 BELOW, MAY NOT BE OFFERED, SOLD, PLEDGED OR OTHERWISE TRANSFERRED UNLESS AND UNTIL REGISTERED UNDER SAID ACT AND LAWS OR IN FORM AND SUBSTANCE SATISFACTORY TO THE COMPANY, S |
|
| May 24, 2012 |
Restated Omnibus Amendment to Convertible Note and Warrant Purchase Agreement Exhibit 10. |
|
| May 24, 2012 |
HYPERION THERAPEUTICS, INC. 2012 OMNIBUS INCENTIVE PLAN TABLE OF CONTENTS 2012 Omnibus Incentive Plan Exhibit 10.15 HYPERION THERAPEUTICS, INC. 2012 OMNIBUS INCENTIVE PLAN TABLE OF CONTENTS Page 1. PURPOSE 1 2. DEFINITIONS 1 3. ADMINISTRATION OF THE PLAN 7 3.1. Board 7 . 3.2 Committee 8 3.3. Terms of Awards 8 3.4. Forfeiture; Recoupment 9 3.5. Repricing 10 3.6. Deferral Arrangement 10 3.7. No Liability 10 3.8. Stock Issuance/Book-Entry 10 4. STOCK SUBJECT TO THE PLAN 11 |
|
| May 24, 2012 |
Amendment #1 to Form S-1 Table of Contents As filed with the Securities and Exchange Commission on May 24, 2012 Registration Statement File No. |
|
| May 24, 2012 |
Agreement by and between Dr. Marshall L. Summar and Medicis Exhibit 10.23 *** INDICATES MATERIAL THAT WAS OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT WAS REQUESTED. ALL SUCH OMITTED MATERIAL WAS FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED. AGREEMENT This Agreement (the “Agreement”) is entered into by an |
|
| May 24, 2012 |
Hogan Lovells US LLP Columbia Square 555 Thirteenth Street, NW Washington, DC 20004 T +1 202 637 5600 F +1 202 637 5910 www. |
|
| May 24, 2012 |
Exhibit 10.24 LOAN AND SECURITY AGREEMENT THIS LOAN AND SECURITY AGREEMENT (this “Agreement”) dated as of April 19, 2012 (the “Effective Date”) between SILICON VALLEY BANK (“Bank”), as collateral agent and Administrative Agent (in such capacity referred to herein as “Agent” or “Collateral Agent”), and the Lenders listed on Schedule 1.1 hereof and party hereto (each, a “Lender” and collectively, th |
|
| May 24, 2012 |
FORM OF SECURED PROMISSORY NOTE $5,000,000 Dated: April 19, 2012 Form of Secured Promissory Note Exhibit 4.8 FORM OF SECURED PROMISSORY NOTE $5,000,000 Dated: April 19, 2012 FOR VALUE RECEIVED, the undersigned, HYPERION THERAPEUTICS, INC., a Delaware corporation (“Borrower”), HEREBY PROMISES TO PAY to (“Lender”) the principal amount of Five Million Dollars ($5,000,000) or such lesser amount as shall equal the outstanding principal balance of the Term Loan made |
|
| May 24, 2012 |
Amended and Restated Bylaws of the Company Exhibit 3.4 HYPERION THERAPEUTICS, INC. a Delaware Corporation AMENDED AND RESTATED BYLAWS As Adopted April 6, 2012 HYPERION THERAPEUTICS, INC. a Delaware Corporation AMENDED AND RESTATED BYLAWS TABLE OF CONTENTS Page ARTICLE I – OFFICES 1 Section 1.1. Registered Office 1 Section 1.2. Other Offices 1 ARTICLE II - STOCKHOLDERS 1 Section 2.1. Place of Meeti |
|
| May 24, 2012 |
License Agreement Exhibit 10.21 *** INDICATES MATERIAL THAT WAS OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT WAS REQUESTED. ALL SUCH OMITTED MATERIAL WAS FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED. EXECUTION COPY LICENSE AGREEMENT THIS LICENSE AGREEMENT (the “Agreement”) is made and entered into as of A |
|
| May 24, 2012 |
Amended and Restated Collaboration Agreement Exhibit 10.20 *** INDICATES MATERIAL THAT WAS OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT WAS REQUESTED. ALL SUCH OMITTED MATERIAL WAS FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED. EXECUTION COPY AMENDED AND RESTATED COLLABORATION AGREEMENT by and between UCYC |
|
| May 24, 2012 |
HYPERION THERAPEUTICS, INC. AMENDED AND RESTATED CERTIFICATE OF INCORPORATION Amended and Restated Certificate of Incorporation of the Company Exhibit 3.2 HYPERION THERAPEUTICS, INC. AMENDED AND RESTATED CERTIFICATE OF INCORPORATION Hyperion Therapeutics, Inc., a Delaware Corporation, (the “Corporation”) hereby certifies as follows. 1. The name of the Corporation is Hyperion Therapeutics, Inc. The Certificate of Incorporation was originally filed with the Secretary of State |
|
| May 24, 2012 |
Exhibit 2.1 *** INDICATES MATERIAL THAT WAS OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT WAS REQUESTED. ALL SUCH OMITTED MATERIAL WAS FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED. EXECUTION COPY ASSET PURCHASE AGREEMENT between UCYCLYD PHARMA, INC., and HYPERION THERAPEUTICS, INC. dated as of March 22, 20 |
|
| May 24, 2012 |
Exhibit 10.22 *** INDICATES MATERIAL THAT WAS OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT WAS REQUESTED. ALL SUCH OMITTED MATERIAL WAS FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED. EXECUTION COPY SETTLEMENT AGREEMENT AND FIRST AMENDMENT TO LICENSE AGREEMENT This Settlement Agreement and First Amendment t |
|
| May 24, 2012 |
HYPERION THERAPEUTICS, INC. 2012 OMNIBUS INCENTIVE PLAN INCENTIVE STOCK OPTION AGREEMENT Form of Incentive Stock Option Agreement Exhibit 10.16 HYPERION THERAPEUTICS, INC. 2012 OMNIBUS INCENTIVE PLAN INCENTIVE STOCK OPTION AGREEMENT Hyperion Therapeutics, Inc., a Delaware corporation (the “Company”), hereby grants an option to purchase shares of its common stock, par value $ per share (the “Option”), to the optionee named below, subject to the vesting and other conditions set forth be |
|
| April 13, 2012 |
HYPERION THERAPEUTICS, INC. EXECUTIVE CHANGE OF CONTROL AND SEVERANCE AGREEMENT Form of Executive Change of Control and Severance Agreement Exhibit 10.11 HYPERION THERAPEUTICS, INC. EXECUTIVE CHANGE OF CONTROL AND SEVERANCE AGREEMENT This Change of Control and Severance Agreement (the “Agreement”) is made and entered into by and between (the “Executive”) and Hyperion Therapeutics, Inc. (the “Company”), effective as of the latest date set forth by the signatures of the parties |
|
| April 13, 2012 |
HYPERION THERAPEUTICS, INC. CONVERTIBLE NOTE AND WARRANT PURCHASE AGREEMENT The October 2011 Purchase Agreement Exhibit 10.4 HYPERION THERAPEUTICS, INC. CONVERTIBLE NOTE AND WARRANT PURCHASE AGREEMENT This Convertible Note and Warrant Purchase Agreement (this “Agreement”) is made as of October 26, 2011 (the “Effective Date”) by and between Hyperion Therapeutics, Inc., a Delaware corporation (the “Company”), and each of the purchasers listed on Exhibit A attached to this A |
|
| April 13, 2012 |
2006 Equity Incentive Plan, as amended Exhibit 10.12 HYPERION THERAPEUTICS, INC. 2006 EQUITY INCENTIVE PLAN ADOPTED BY BOARD ON: DECEMBER 20, 2006 APPROVED BY STOCKHOLDERS: DECEMBER 20, 2006 TERMINATION DATE: DECEMBER 19, 2016 (AS AMENDED ON JUNE 25, 2009 AND JUNE 30, 2010) 1. GENERAL. (a) Eligible Stock Award Recipients. The persons eligible to receive Stock Awards are Employees, Directors and Co |
|
| April 13, 2012 |
FORM OF INDEMNIFICATION AGREEMENT Form of Indemnification Agreement Exhibit 10.5 FORM OF INDEMNIFICATION AGREEMENT THIS AGREEMENT (the “Agreement”) is made and entered into as of , 2012 between Hyperion Therapeutics, Inc., a Delaware corporation (the “Company”), and (“Indemnitee”). This Agreement will become effective only upon the effectiveness of the Company’s registration statement on Form S-1 in connection with the Company’s i |
|
| April 13, 2012 |
WARRANT TO PURCHASE SHARES OF COMMON STOCK Form of Warrant to Purchase Common Stock Exhibit 4.4 WARRANT TO PURCHASE SHARES OF COMMON STOCK THIS WARRANT AND THE SECURITIES ISSUABLE UPON THE EXERCISE HEREOF HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED. THEY MAY NOT BE SOLD, OFFERED FOR SALE, PLEDGED, HYPOTHECATED OR OTHERWISE TRANSFERRED EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT |
|
| April 13, 2012 |
Form of Convertible Unsecured Promissory Note Exhibit 4.7 THESE SECURITIES HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR ANY APPLICABLE STATE SECURITIES LAWS AND HAVE BEEN ACQUIRED FOR INVESTMENT AND NOT WITH A VIEW TO, OR IN CONNECTION WITH, THE SALE OR DISTRIBUTION THEREOF. NO SUCH SALE OR DISTRIBUTION MAY BE EFFECTED WITHOUT AN EFFECTIVE REGISTRATION STATEMENT OR QUA |
|
| April 13, 2012 |
HYPERION THERAPEUTICS, INC. 2006 EQUITY INCENTIVE PLAN AMENDMENT April 15, 2011 Exhibit 10.13 HYPERION THERAPEUTICS, INC. 2006 EQUITY INCENTIVE PLAN AMENDMENT April 15, 2011 The 2006 Equity Incentive Plan (the “Plan”), adopted as of December 20, 2006, of Hyperion Therapeutics, Inc., a Delaware corporation (the “Company”), is hereby amended pursuant to Section 2(b)(vi) thereof to increase the number of shares of Common Stock that may be issued thereunder. 1. DEFINITIONS Capita |
|
| April 13, 2012 |
HYPERION THERAPEUTICS, INC. Executive Employment Agreement Employment Agreement - Donald J. Santel Exhibit 10.6 HYPERION THERAPEUTICS, INC. Executive Employment Agreement This employment agreement (“Agreement”) dated and effective as of April 9, 2012 (the “Effective Date”) is between Hyperion Therapeutics, Inc., a Delaware corporation (the “Company”) and Donald J. Santel, a resident of San Francisco, California (“Executive”). WHEREAS, Executive began his |
|
| April 13, 2012 |
Offer Letter Agreement - Bruce F. Scharschmidt, M.D. Exhibit 10.8 March 14, 2008 Bruce F. Scharschmidt, M.D. [Address] Dear Bruce: Hyperion Therapeutics, Inc. (the “Company”) is pleased to extend an offer to join the Company as a full-time employee. Your offer shall be on the following terms: 1. Position. Upon approval by the Board of Directors, you will be appointed Senior Vice President, Chief M |
|
| April 13, 2012 |
Offer Letter Agreement - Klara A. Dickinson Exhibit 10.9 September 7, 2007 Klara A. Dickinson [Address] Dear Klara: Hyperion Therapeutics, Inc. (the “Company”) is pleased to an offer to join the Company as a full-time employee. This letter amends and restates in its entirety the previous conditional offer letter (“Conditional Offer Letter”). Your offer shall be on the following terms: 1. Position. |
|
| April 13, 2012 |
Form of Warrant to Purchase Preferred Stock Exhibit 4.5 WARRANT TO PURCHASE SHARES OF PREFERRED STOCK THIS WARRANT AND THE SECURITIES ISSUABLE UPON THE EXERCISE HEREOF HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED. THEY MAY NOT BE SOLD, OFFERED FOR SALE, PLEDGED, HYPOTHECATED OR OTHERWISE TRANSFERRED EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIE |
|
| April 13, 2012 |
Offer Letter Agreement - Christine A. Nash Exhibit 10.10 September 7, 2007 Christine Nash [Address] Dear Christine: Hyperion Therapeutics, Inc. (the “Company”) is pleased to an offer to join the Company as a full-time employee. This letter amends and restates in its entirety the previous conditional offer letter (“Conditional Offer Letter”). Your offer shall be on the following terms: 1. Position. |
|
| April 13, 2012 |
Registration Statement - FORM S-1 Form S-1 Table of Contents As filed with the Securities and Exchange Commission on April 13, 2012 Registration Statement File No. |
|
| April 13, 2012 |
Second Amended and Restated Investor Rights Agreement Exhibit 10.1 HYPERION THERAPEUTICS, INC. SECOND AMENDED AND RESTATED INVESTOR RIGHTS AGREEMENT HYPERION THERAPEUTICS, INC. SECOND AMENDED AND RESTATED INVESTOR RIGHTS AGREEMENT THIS SECOND AMENDED AND RESTATED INVESTOR RIGHTS AGREEMENT (the “Agreement”) is entered into as of the 29th day of June, 2009, by and among Hyperion Therapeutics, Inc., |
|
| April 13, 2012 |
Office Lease Exhibit 10.18 OFFICE LEASE 601 GATEWAY BOULEVARD GATEWAY CENTER, LLC, a Delaware limited liability company, as Landlord, and HYPERION THERAPEUTICS, INC. a Delaware corporation, as Tenant. TABLE OF CONTENTS Page ARTICLE 1 PREMISES, BUILDING, PROJECT, AND COMMON AREAS 4 ARTICLE 2 LEASE TERM 6 ARTICLE 3 BASE RENT 10 ARTICLE 4 ADDITIONAL RENT 10 ARTICLE 5 USE OF PREMISES 18 ARTICLE 6 SERV |
|
| April 13, 2012 |
Offer Letter Agreement - Jeffrey Farrow Exhibit 10.7 November 12, 2009 Jeffrey Farrow [Address] Dear Jeff: Hyperion Therapeutics, Inc. (the “Company”) is pleased to extend an offer to join the Company as a full-time employee based on the following terms: 1. Position. The Company proposes to offer you the position of Vice President, Finance reporting to the Chief Executive Officer. By signing this |
|
| April 13, 2012 |
601 GATEWAY BOULEVARD FIRST AMENDMENT TO OFFICE LEASE First Amendment to Office Lease Exhibit 10.19 601 GATEWAY BOULEVARD FIRST AMENDMENT TO OFFICE LEASE This FIRST AMENDMENT TO OFFICE LEASE (this “First Amendment”) is made and entered into as of October 31, 2011 by and between GATEWAY CENTER, LLC, a Delaware limited liability company (“Landlord”), and HYPERION THERAPEUTICS, INC., a Delaware corporation (“Tenant”). RECITALS A. Landlord and Tenant ent |
|
| April 13, 2012 |
Amended and Restated Bylaws of the Company Exhibit 3.3 AMENDED AND RESTATED BYLAWS OF HYPERION THERAPEUTICS, INC. (A DELAWARE CORPORATION) TABLE OF CONTENTS PAGE ARTICLE I OFFICES 1 Section 1. Registered Office 1 Section 2. Other Offices 1 ARTICLE II CORPORATE SEAL 1 Section 3. Corporate Seal 1 ARTICLE III STOCKHOLDERS’ MEETINGS 1 Section 4. Place of Meetings 1 Section 5. Annual Meeting 1 Section |
|
| April 13, 2012 |
Form of Convertible Unsecured Promissory Note Form of Convertible Unsecured Promissory Note Exhibit 4.6 Form of Convertible Unsecured Promissory Note THESE SECURITIES HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR ANY APPLICABLE STATE SECURITIES LAWS AND HAVE BEEN ACQUIRED FOR INVESTMENT AND NOT WITH A VIEW TO, OR IN CONNECTION WITH, THE SALE OR DISTRIBUTION THEREOF. NO SUCH SALE OR DISTRIBUTION MAY BE EFFECTED WITH |
|
| April 13, 2012 |
List of Subsidiaries Name Jurisdiction of Incorporation Hyperion Therapeutics Limited United Kingdom Subsidiaries of the Company Exhibit 21.1 List of Subsidiaries Name Jurisdiction of Incorporation Hyperion Therapeutics Limited United Kingdom |
|
| April 13, 2012 |
Warrant to Purchase Common Stock issued to Keelin Reeds Exhibit 4.3 THIS WARRANT AND THE UNDERLYING SECURITIES HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”). THEY MAY NOT BE SOLD, OFFERED FOR SALE, PLEDGED OR HYPOTHECATED IN THE ABSENCE OF AN EFFECTIVE REGISTRATION STATEMENT AS TO SUCH SECURITIES UNDER THE ACT OR AN OPINION OF COUNSEL SATISFACTORY TO THE COMPANY |
|
| April 13, 2012 |
HYPERION THERAPEUTICS, INC. CONVERTIBLE NOTE AND WARRANT PURCHASE AGREEMENT The April 2011 Purchase Agreement Exhibit 10.2 HYPERION THERAPEUTICS, INC. CONVERTIBLE NOTE AND WARRANT PURCHASE AGREEMENT This Convertible Note and Warrant Purchase Agreement (this “Agreement”) is made as of April 1, 2011 (the “Effective Date”) by and between Hyperion Therapeutics, Inc., a Delaware corporation (the “Company”), and each of the purchasers listed on Exhibit A attached to this Agreem |
|
| April 13, 2012 |
AMENDED AND RESTATED CERTIFICATE OF INCORPORATION HYPERION THERAPEUTICS, INC. Amended and Restated Certificate of Incorporation of the Company Exhibit 3.1 AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF HYPERION THERAPEUTICS, INC. Hyperion Therapeutics, Inc., a corporation organized and existing under and by virtue of the Delaware General Corporation Law, hereby certifies as follows: 1. The name of this corporation is Hyperion Therapeutics, Inc. and the date of filing |
|
| April 13, 2012 |
Form of Option Agreement under 2006 Equity Incentive Plan Exhibit 10.14 HYPERION THERAPEUTICS, INC. 2006 EQUITY INCENTIVE PLAN OPTION AGREEMENT (INCENTIVE STOCK OPTION OR NONSTATUTORY STOCK OPTION) Pursuant to your Stock Option Grant Notice (“Grant Notice”) and this Option Agreement, Hyperion Therapeutics, Inc. (the “Company”) has granted you an option under its 2006 Equity Incentive Plan (the “Pl |
